Purdue Pharma, Actavis Settle OxyContin Patent Litigation

Purdue Pharma LP settled a patent- infringement lawsuit against Actavis (ACT) Inc. over the pain medication OxyContin.

Purdue will grant Actavis a license to sell “defined quantities” of a generic version of the drug as early as next year, the companies said in a statement today. Actavis, based in Morristown, New Jersey, said it had infringed the Purdue patents.

“Today’s agreement will promote competition and allow for availability of generic formulations of reformulated OxyContin,” according to the statement. “This resolution relieves us of the risks, distractions and costs of continued litigation.”

The U.S. Food and Drug Administration said this month that generic drug companies will be barred from making older versions of OxyContin that aren’t resistant to tampering.

Purdue, based in Stamford, Connecticut, replaced an older version of OxyContin with a tamper-resistant formulation. The drug, obtained illegally on the black market, has been abused by addicts.

To contact the reporter on this story: Don Jeffrey in New York at djeffrey1@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.